NCT04754100: Phase 1 - AGENT-797 in Participants With Relapsed/Refractory Multiple Myeloma

• NCT04754100: Phase 1 - AGENT-797 in Participants With Relapsed/Refractory Multiple Myeloma

This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in patients with relapsed or refractory multiple myeloma.

Sponsor

MiNK Therapeutics

Agenus Inc. ( MiNK Therapeutics )

---

ClinicalTrials.gov Identifier: NCT04754100

Official Title: A PHASE I OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND PRELIMINARY CLINICAL ACTIVITY OF ALLOGENEIC INVARIANT NATURAL KILLER (INKT) NON-TRANSDUCED CELLS (AGENT-797) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

First Posted : February 15, 2021

Click here for details on ClinicalTrials.gov

---

agenT-797

Allogeneic Invariant Natural Killer T-cells agenT-797

Allogeneic Invariant Natural Killer T-cells agenT-797 (Code C178501)

AGENT 797

AgenT-797

AGENT-797

agenT797

Allogeneic iNKT agenT-797

---

- Kentucky: Norton Cancer Institute Louisville

- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston

---

Drug: agenT-797

---

Locations

United States, Kentucky

United States, Massachusetts